Cystic Fibrosis
Conditions
Keywords
Cystic Fibrosis, Roscovitine, Seliciclib, CYC202
Brief summary
This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study. The aim of this study is to assess the safety of increasing doses of roscovitine administered orally for 4 cycles of 4 consecutive days (treatment on) separated by a 3 days treatment free period (treatment off) in adult CF subjects with Cystic Fibrosis carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa. This study involved 36 Cystic Fibrosis patients: 24 treated and 12 controls.
Detailed description
ROSCO-CF is a phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and effects of (R)-roscovitine in subjects with Cystic Fibrosis carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa. The aim of this study is to assess the safety of increasing doses of roscovitine administered orally for 4 cycles of 4 consecutive days (treatment on) separated by a 3 days treatment free period (treatment off) in 36 adult cystic fibrosis subjects. These 36 patients will be allocated to 3 groups of 12 subjects who will be randomized in a 2:1 ratio (active drug to matching placebo). In each group, 8 patients will receive roscovitine (200 mg, 400 mg, 2 X 400 mg in group 1, 2 and 3, respectively) and 4 will receive a matching placebo. Treatment will be provided by oral administration of capsules. Each patient will receive the same treatment throughout the 28 day study. This phase II trial will give some preliminary information about safety and hints of effects of a new experimental treatment. If the data suggest that a short term treatment with roscovitine provides a safe, effective and convenient approach for CF patients chronically infected with Pseudomonas aeruginosa, patients participating in this proof of concept trial will be offered to participate in further longer term studies.
Interventions
DRUGRoscovitine
Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
DRUGPlacebo
The placebo treatment is lactose capsule.
Sponsors
ManRos Therapeutics
Cyclacel Pharmaceuticals, Inc.
University Hospital, Brest
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female aged over 18 years of age on the date of informed consent; * Diagnosed CF patients. Confirmed diagnosis of CF (Rosenstein and Cutting, 1998); * Patients carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation, genotype to be confirmed at screening; * Forced expiratory volume at 1 second (FEV1) 40% * Chronic lung Pseudomonas aeruginosa infection according to the definition from the French Consensus Conference; * Able to understand and comply with all protocol requirements, restrictions and instructions and likely to complete the study as planned (as judged by the investigator); * Provide written informed consent prior to the performance of any study-related procedure;
Exclusion criteria
* Acute upper or lower respiratory infection, pulmonary exacerbation or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before V2; * Recent patient reported history of: * non recovered viral upper respiratory tract infection * solid organ or hematological transplantation * Burkholderia cepacia complex or Non Tuberculous Mycobacteria (NTM) respiratory tract infection; * Undergone major surgery within 1 month prior to screening; * Currently treated allergic broncho-pulmonary aspergillosis (ABPA); * Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1C \>8%; * Hemoptysis more than 60 mL at any time within 4 weeks prior to first study drug administration (V2); * History of any other comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject; * Any other clinically significant conditions (not associated with the study indication) at Screening (V1) which might interfere with the assessment of this study; * Any of the following abnormal laboratory values at screening: * Hemoglobin \<10 g/dL * Abnormal liver function * Serum K+ \<3,5 mmol/L * Abnormal renal function * Any clinically significant laboratory abnormalities; * Patients who have clinically significant impairment in cardiovascular function; * Concomitant disease(s) that could prolong the QT interval; * Patients with a history of alcohol or drug abuse in the past year; * Patients with a history of noncompliance to medical regimens and patients or caregivers who are considered potentially unreliable; * Use of one (or several) prohibited medications and/or food; * Administration of any investigational drug within 30 days prior to Screening (V1) or 5 half-lives, whichever is longer; * Use of systemic anti-pseudomonal antibiotics within 28 days prior to first study drug administration (V2). However use of inhaled anti-pseudomonal antibiotic treatment is allowed if initiated for more than 28 days; * Use of loop diuretics within 7 days prior to first study drug administration (V2); * Pregnant or nursing females.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of increasing doses of Roscovitine | 3 months | The primary objective of this study is to assess the safety of increasing doses of roscovitine administered orally for 4 cycles of 4 consecutive days (treatment on) separated by a 3 days treatment free period (treatment off) in adult CF subjects who carrying 2 Cystic Fibrosis causing mutations with at least F508del mutation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK parameters | 3 months | PK parameters: Maximum Concentration (Cmax), Time to reach Cmax (Tmax), Area Under Curve (AUCt and AUCInf), Half-life (t1/2) for roscovitine and its M3 metabolite. |
| Pro- and anti-inflammatory cytokines | 3 months | Monitoring the levels of pro- and anti-inflammatory cytokines, in particular: interleukin (IL)-17A, IL-5, IFN-γ, IL-1 receptor antagonist, IL-4, IL-6, IL-10, tumor necrosis factor-alpha, and IL-18 on V2, V3 and V7 (Completion Visit) |
| C-reactive protein | 3 months | Change in C-reactive protein (CRP) at each visit from V1 (Screening) up to V7 (Completion) |
| Cystic Fibrosis Questionnaire-Revised | 3 months | Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) at each visit from V1 up to V8 (Safety Follow-up) |
| Change in the concentration of Pseudomonas Aeruginosa | 3 months | Change in the concentration (CFU/mL) of Pseudomonas aeruginosa in the sputum at each visit from V1 (Screening) up to V7 (Completion Visit). |
| Forced expiratory volume in 1 second | 3 months | Change in forced expiratory volume in 1 second (FEV1) at each visit from V1 (Screening) up to V7 (Completion Visit) |
| Sweat Chloride Concentration | 3 months | Change in Sweat Chloride Concentration at V2, V3, V5 and V7 (Completion) |
| Nasal Potential Difference | 3 months | Change in Nasal Potential Difference (NPD) at V1 (Screening) and V6 (for patients included in Paris Cochin CF Center) |
| Pain questionnaire | 3 months | Evaluate of the pain and of the impact of the pain in patients with cystic fibrosis |
| Body Mass Index | 3 months | Change in body mass index (BMI) at each visit from V1 (Screening) up to V7 (Completion Visit) |
Countries
France
Outcome results
None listed